Bicyclic or tricyclic heterocyclic compound

US10065972B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10065972-B2
Application numberUS-201514891845-A
CountryUS
Kind codeB2
Filing dateApr 22, 2015
Priority dateApr 23, 2014
Publication dateSep 4, 2018
Grant dateSep 4, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention provides a novel bicyclic or tricyclic heterocyclic compound represented by the formula (I) wherein ring A is an optionally substituted aromatic group, one of X 1 and X 2 is a carbon atom, and the other is a nitrogen atom, X 3 is a nitrogen atom, or CR 2 , X 4 is a nitrogen atom, or CR 3 , X 5 is a sulfur atom, or —CH═CH—, Z 1 is an oxygen atom, —C(R 6 )(R 7 )—, —NH—, —C(R 6 )(R 7 )—NH—, —NH—C(R 6 )(R 7 )—, —C(R 6 )(R 7 )—O—, —O—C(R 6 )(R 7 )—, or a single bond, one of Z 2 and Z 3 is CH and the other is a nitrogen atom, or both are nitrogen atoms, and other symbols are as defined in the DESCRIPTION, or a pharmacologically acceptable salt thereof.

First claim

Opening claim text (preview).

The invention claimed is: 1. A compound represented by the formula (I): wherein ring A is an optionally substituted aromatic group, one of X 1 and X 2 is a carbon atom, and the other is a nitrogen atom, X 3 is a nitrogen atom, or CR 2 , X 4 is a nitrogen atom, or CR 3 , X 5 is a sulfur atom, or —CH═CH—, Z 1 is an oxygen atom, —C(R 6 )(R 7 )—, —NH—, —C(R 6 )(R 7 )—NH—, —NH—C(R 6 )(R 7 )—, —C(R 6 )(R 7 )—O—, or —O—C(R 6 )(R 7 )—, or is a single bond directly linking the adjacent carbonyl group to ring A one of Z 2 and Z 3 is CH and the other is a nitrogen atom, or both are nitrogen atoms, R 1 is a hydrogen atom, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, an optionally substituted nonaromatic heterocyclic group, or a halogen atom, R 2 is a hydrogen atom, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted amino, optionally substituted aryl, an optionally substituted nonaromatic heterocyclic group, optionally substituted heteroaryl, optionally substituted alkoxy, or optionally substituted cycloalkoxy, or, R 1 and R 2 are bonded to each other to form, together with the adjacent X 2 and carbon atom, an optionally substituted ring, R 3 is a hydrogen atom, optionally substituted alkyl, optionally substituted cycloalkyl, or a halogen atom, R 4 and R 5 are each independently a hydrogen atom, or optionally substituted alkyl, or, R 4 and R 5 are bonded to each other to form, together with the adjacent Z 2 and Z 3 , an optionally substituted nitrogen-containing non-aromatic heterocycle, R 6 and R 7 are each independently a hydrogen atom, optionally substituted alkyl, or optionally substituted cycloalkyl, or, R 6 and R 7 are bonded to each other to form, together with the adjacent carbon atom, an optionally substituted cycloalkane, a part represented by the following formula in the aforementioned formula (I): is (A) when X 1 is a carbon atom and X 2 is a nitrogen atom, a group represented by the following formula (i-a):  and (B) when X 1 is a nitrogen atom and X 2 is a carbon atom, a group represented by the following formula (i-b): provided (a) when a part represented by the following formula in the aforementioned formula (I): is a group represented by the formula (ii-a): (a-1) Z 2 is a nitrogen atom, and Z 3 is CH or a nitrogen atom; (a-2) Z 2 is CH, and Z 3 is a nitrogen atom, and a part represented by the following formula in the formula (I): is a group represented by the formula (v-x):  or (a-3) Z 2 is CH, and Z 3 is a nitrogen atom, and a part represented by the following formula in the formula (I): is a group represented by the formula (v-y): and a part represented by the following formula in the formula (I): is a group represented by the formula (iii-a), (iii-b), or (iii-c): wherein R 6x and R 7x are each optionally substituted alkyl or R 6x and R 7x are bonded to each other to form, together with the adjacent carbon atom, an optionally substituted cycloalkane, R 8x is halogenoalkyl, or a fluorine atom, and (b) when a part represented by the following formula in the aforementioned formula (I): is a group represented by the formula (ii-b): (b-1) Z 2 is a nitrogen atom, and Z 3 is CH or a nitrogen atom; or (b-2) Z 2 is CH, and Z 3 is a nitrogen atom, R 4 and R 5 are bonded to each other to form, together with the adjacent Z 2 and Z 3 , an optionally substituted nitrogen-containing non-aromatic heterocycle, and a part represented by the following formula in the formula (I): is a group represented by the formula (iii-d): or a pharmacologically acceptable salt thereof. 2. The compound according to claim 1 , wherein, in the formula (I), the part represented by the following formula: is a group represented by the formula (iv-a), (iv-b), (iv-c), (iv-d), (iv-e), (iv-f), or (iv-g): or a pharmacologically acceptable salt thereof. 3. The compound according to claim 2 , wherein ring A is a 5- to 11-membered monocyclic or bicyclic aromatic group optionally containing, besides carbon atom, 1-4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom, wherein said aromatic group is optionally substituted by the same or different 1, 2 or 3 groups selected from the group consisting of (1) alkyl optionally substituted by the same or different 1-7 groups selected from the group consisting of amino optionally substituted by 1 or 2 alkyls, alkoxy, and a halogen atom; (2) cyano; (3) amino optionally substituted by 1 or 2 alkyls; (4) alkoxy optionally substituted by 1-7 halogen atoms; and (5) a halogen atom, R 1 is (a) a hydrogen atom; (b) alkyl optionally substituted by the same or different 1-7 groups selected from the group consisting of amino (wherein said amino is optionally substituted by the same or different 1 or 2 groups selected from the group consisting of alkyl, halogenoalkyl, and alkoxycarbonyl), hydroxy, alkoxy, a halogen atom, phenyl, alkoxyphenyl, and a 4- to 7-membered monocyclic nonaromatic heterocyclic group containing, besides carbon atom, 1 or 2 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom, wherein said nonaromatic heterocyclic group is optionally substituted by the same or different 1, 2 or 3 groups selected from the group consisting of alkyl, and alkoxycarbonyl; (c) cycloalkyl optionally substituted by 1, 2 or 3 alkoxyalkyls; (d) a halogen atom; (e) phenyl; or (f) a 4- to 7-membered monocyclic nonaromatic heterocyclic group containing, besides carbon atom, 1 or 2 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom, wherein said nonaromatic heterocyclic group is optionally substituted by the same or different 1, 2

Assignees

Inventors

Classifications

  • Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

  • for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

  • Antidepressants · CPC title

  • Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia · CPC title

  • Drugs for disorders of the nervous system · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10065972B2 cover?
The present invention provides a novel bicyclic or tricyclic heterocyclic compound represented by the formula (I) wherein ring A is an optionally substituted aromatic group, one of X 1 and X 2 is a carbon atom, and the other is a nitrogen atom, X 3 is a nitrogen atom, or CR 2 , X 4 is a nitrogen atom, or CR 3 , X 5 is a sulfur atom, or —CH═CH—, Z…
Who is the assignee on this patent?
Mitsubishi Tanabe Pharma Corp
What technology area does this patent fall under?
Primary CPC classification C07D513/04. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Sep 04 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).